Humacyte, Inc. (NASDAQ:HUMA) Stock Has Average Target Price of $6.54 According to Brokerages

Shares of Humacyte, Inc. (NASDAQ:HUMA) have earned an average recommendation of “Moderate Buy” from the eight analysts that are currently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation and seven have issued a buy recommendation on the company. The average 12-month price target among brokers that have covered the stock in the last year is $6.54.

HUMA has been the topic of a number of recent research reports. Weiss Ratings reissued a “sell (e+)” rating on shares of Humacyte in a research report on Wednesday, July 8th. Barclays initiated coverage on Humacyte in a research note on Tuesday. They issued a “positive” rating for the company. TD Cowen reduced their target price on Humacyte from $1.50 to $1.25 and set a “buy” rating for the company in a research report on Wednesday, June 17th. BTIG Research reiterated a “buy” rating and set a $2.00 price target on shares of Humacyte in a research note on Wednesday, August 12th. Finally, Benchmark decreased their target price on shares of Humacyte from $2.00 to $1.00 and set a “speculative buy” rating on the stock in a research report on Thursday, August 13th.

Institutional Investors Weigh In On Humacyte

Large investors have recently modified their holdings of the stock. Alyeska Investment Group L.P. acquired a new stake in shares of Humacyte in the 2nd quarter valued at $4,700,000. BlackRock Inc. bought a new position in Humacyte during the 2nd quarter valued at about $3,777,000. GSA Capital Partners LLP acquired a new position in Humacyte in the second quarter valued at about $785,000. Private Advisor Group LLC boosted its holdings in shares of Humacyte by 48.3% in the 1st quarter. Private Advisor Group LLC now owns 832,799 shares of the company’s stock worth $505,000 after acquiring an additional 271,222 shares in the last quarter. Finally, HBK Investments L P acquired a new position in shares of Humacyte in the 2nd quarter worth approximately $617,000. 44.71% of the stock is currently owned by institutional investors.

Humacyte Price Performance

NASDAQ:HUMA opened at $0.48 on Wednesday. The stock has a market cap of $132.79 million, a P/E ratio of -0.98 and a beta of 2.44. Humacyte has a one year low of $0.47 and a one year high of $1.97. The company has a fifty day moving average price of $0.61 and a 200 day moving average price of $0.77. The company has a debt-to-equity ratio of 2.07, a current ratio of 6.21 and a quick ratio of 5.74.

Humacyte (NASDAQ:HUMA) last issued its quarterly earnings results on Wednesday, August 12th. The company reported ($0.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.05). Humacyte had a negative net margin of 4,556.29% and a negative return on equity of 983.32%. The company had revenue of $0.41 million during the quarter, compared to the consensus estimate of $1.04 million. Analysts anticipate that Humacyte will post -0.4 earnings per share for the current year.

Humacyte Company Profile

Humacyte, Inc is a biotechnology company developing and manufacturing bioengineered human tissues for use in regenerative medicine. Its technology platform is designed to produce off-the-shelf, implantable tissues that can be stored and transported for use when needed, potentially reducing reliance on tissue obtained directly from patients or human donors.

The company’s primary product is SYMVESS, an acellular tissue-engineered vascular graft designed to replace or repair damaged blood vessels.